CAR-T cells targeting the CD19 surface antigen expressed in various B cell malignancies have led to unprecedented results in B-ALL and DLBCL, which resulted in the approval of Axicabtagene ciloleucel (Yescarta®) and Tisagenlecleucel (Kymriah®) for relapsed/refractory B cell lymphomas and B-ALL [20,21,22]. Here, CD19 is linked to acute lymphoblastic leukemia.